Mankind Pharma Limited (MANKIND) secures exclusive in-licensing agreement for Insulin Degludec and Insulin Degludec + Aspart for India, expanding its diabete.
Mankind Pharma Limited (NSE: MANKIND) drops 5% intraday to ₹2441.0, experiencing profit-taking following a recent breakout..
Mankind Pharma Limited (NSE: MANKIND) reports strong Q1FY27 with revenue up 13%, EBITDA growth of 25%, and PAT growth of 29%.
Mankind Pharma Limited (MANKIND) reported a 11.8% revenue increase and an adjusted EBITDA margin of 27.1% in Q4 FY26.